Personalized intensification of insulin therapy in type 2 diabetes – does a basal–bolus regimen suit all patients?

References

• Nyalakonda K, Sharma T, Ismail-Beigi F. Preservation of beta-cell function in type 2 diabetes. Endocr Pract 2010;16:1038-55
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14:228-33
   PubMed Web of Science ®Google Scholar
• Giugliano D, Tracz M, Shah S, et al. Initiation and gradual intensification of premixed insulin lispro therapy versus basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care 2014;37:372-80
   PubMed Web of Science ®Google Scholar
• Owens DR. Stepwise intensification of insulin therapy in type 2 diabetes management – exploring the concept of the basal-plus approach in clinical practice. Diabet Med 2013;30:276-88
   PubMed Web of Science ®Google Scholar
• Meneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med 2013;126 (9 Suppl 1):S28-S37
   PubMed Web of Science ®Google Scholar
• Garber AJ. Methods to enhance delivery of prandial insulin and basal-prandial insulin. Diabetes Obes Metab 2013;15(Suppl 1):11-17
   PubMed Web of Science ®Google Scholar
• Farcasiu E, Ivanyi T, Mozejko-Pastewka B, et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clin Ther 2011;33:1682-93
   PubMed Web of Science ®Google Scholar
• Unnikrishnan AG, Wangnoo SK, Joshi SR, et al. Physician perceptions and practices in management of diabetes in India: results from the IMPROVE Control program. Indian J Endocrinol Metab 2012;16(Suppl 2):S428-S9
   PubMedGoogle Scholar
• Blak BT, Smith HT, Hards M, et al. A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet Med 2012;29:e191-8
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1. 14 May 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=Guideline+on+clinical+investigation+of+medicinal+products+in+the+treatment+or+prevention+of+diabetes+mellitus&btnG=Search&mid= [Last accessed 5 May 2015]
   Google Scholar
• Food and Drug Administration. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance, February 2008. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071624.pdf [Last accessed 5 May 2015]
   Google Scholar
• Beisswenger PJ, Brown WV, Ceriello A, et al.; IOOI Study Investigators. Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with type 2 diabetes. Diabet Med 2011;28:1088-95
   PubMed Web of Science ®Google Scholar
• Bu S, Guo XH, Yang WY, et al. [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen] [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87:3115-18
   PubMedGoogle Scholar
• Clements MR, Tits J, Kinsley BT, et al. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008;10:229-37
   PubMed Web of Science ®Google Scholar
• Davies M, Sinnassamy P, Storms F, Gomis R; AT.LANTUS Study Group. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 2008;79:368-75
   PubMed Web of Science ®Google Scholar
• Heise T, Eckers U, Kanc K, et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008;10:479-85
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract 2009;15:343-8
   PubMed Web of Science ®Google Scholar
• Huang QX, Lou FC, Wang P, et al. Basal insulin therapy strategy is superior to premixed insulin therapy in the perioperative period blood glucose management. Chin Med J (Engl) 2013;126:4030-6
   PubMed Web of Science ®Google Scholar
• Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8:448-55
   PubMed Web of Science ®Google Scholar
• McNally PG, Dean JD, Morris AD, et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007;30:1044-8
   PubMed Web of Science ®Google Scholar
• Schiel R, Müller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study. Exp Clin Endocrinol Diabetes 2007;115:627-33
   PubMed Web of Science ®Google Scholar
• Schiel R, Müller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes 2008;116:58-64
   PubMed Web of Science ®Google Scholar
• Schwartz S, Sievers R, Strange P, et al.; INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43
   PubMed Web of Science ®Google Scholar
• Testa MA, Gill J, Su M, et al. Comparative effectiveness of basal–bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. J Clin Endocrinol Metab 2012;97:3504-14
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014;16:396-402
   PubMed Web of Science ®Google Scholar
• Tinahones FJ, Gross JL, Onaca A, et al. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab 2014;16:963-70
   PubMed Web of Science ®Google Scholar
• Malek R, Ajili F, Assaad-Khalil SH, et al. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: results of a 50-week randomized clinical trial of stepwise insulin intensification. Diabetes Metab 2015;41:223-30
   PubMed Web of Science ®Google Scholar
• Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group. Comparison between a basal–bolus and a premixed insulin regimen in individuals with type 2 diabetes: results of the GINGER study. Diabetes Obes Metab 2010;12:115-23
   PubMed Web of Science ®Google Scholar
• Miser WF, Arakaki R, Jiang H, et al. Randomized, open-label, parallel-group evaluations of basal–bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32:896-908
   PubMed Web of Science ®Google Scholar
• Liebl A, Prager R, Binz K, et al.; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52
   PubMed Web of Science ®Google Scholar
• Masuda H, Sakamoto M, Irie J, et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients. Diabetes Obes Metab 2008;10:1261-5
   PubMed Web of Science ®Google Scholar
• Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008;7:16
   PubMed Web of Science ®Google Scholar
• Shanmugasundar G, Bhansali A, Walia R, et al. Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – a pilot study. Indian J Med Res 2012;135:78-83
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal–bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:511-19
   PubMed Web of Science ®Google Scholar
• Jain SM, Mao X, Escalante-Pulido M, et al. Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:967-75
   PubMed Web of Science ®Google Scholar
• Bowering K, Reed VA, Felicio JS, et al. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet Med 2012;29:e263-72
   PubMed Web of Science ®Google Scholar
• Levin PA, Zhang Q, Mersey JH, et al. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin Ther 2011;33:841-50
   PubMed Web of Science ®Google Scholar
• Green AJ, Fox KM, Grandy S; SHIELD Study Group. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012;96:313-18
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011;13:1008-19
   PubMed Web of Science ®Google Scholar
• Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin 2011;27:1431-8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl 1):S14-S80
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2011;92:1-10
   PubMed Web of Science ®Google Scholar
• Dieuzeide G, Chuang LM, Almaghamsi A, et al. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal–bolus insulin regimens in the A1chieve study. Prim Care Diabetes 2014;8:111-17
   PubMed Web of Science ®Google Scholar
• Mathieu C, Storms F, Tits J, et al. Switching from premixed insulin to basal–bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin Belg 2013;68:28-33
   PubMed Web of Science ®Google Scholar
• Jia W, Xiao X, Ji Q, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal–bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol 2015;3:254-62
   PubMed Web of Science ®Google Scholar
• Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2013;36:1779-88
   PubMed Web of Science ®Google Scholar